mApoE-PA-LIP

mApoE-PA-LIP is a multifunctional, bifunctionalized liposome designed for the treatment of Alzheimer's disease. It combines a peptide sequence derived from apolipoprotein E (mApoE) to enhance blood-brain barrier (BBB) transport, and phosphatidic acid (PA), a high-affinity ligand for beta-amyloid (Aβ) peptides. The liposome can bind Aβ oligomers and fibrils, inhibit amyloid aggregation, and disaggregate preformed fibrils. Its mechanism is based on the peripheral "sink effect": after administration, it acts in the bloodstream to sequester circulating Aβ, thereby promoting Aβ efflux from the brain and reducing cerebral amyloid burden. In preclinical studies, mApoE-PA-LIP was shown to decrease brain amyloid plaque load and ameliorate cognitive deficits in Alzheimer's mouse models, without significant direct entry into the brain. This candidate is considered a nanotechnological approach aimed at slowing neurodegeneration by modulating amyloid burden, rather than eliminating the underlying cause of excess amyloid production[1][3][5][7].